11553 related articles for article (PubMed ID: 12296474)
41. [On the behalf of the Japanese Society of Biological Response Modifiers].
Ishihara K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):906-11. PubMed ID: 2730029
[TBL] [Abstract][Full Text] [Related]
42. Biological modifiers and their role in cancer therapy.
Nethersell AB
Ann Acad Med Singap; 1990 Mar; 19(2):223-34. PubMed ID: 2189342
[TBL] [Abstract][Full Text] [Related]
43. Biological response modifiers in cancer.
Reang P; Gupta M; Kohli K
MedGenMed; 2006 Nov; 8(4):33. PubMed ID: 17415315
[TBL] [Abstract][Full Text] [Related]
44. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1994; 15():190-212. PubMed ID: 7779586
[No Abstract] [Full Text] [Related]
45. Immunological monitoring and clinical trials of biological response modifiers.
Baseler MW; Kopp WC; Urba WJ
Cancer Chemother Biol Response Modif; 1993; 14():249-83. PubMed ID: 7508729
[No Abstract] [Full Text] [Related]
46. Paradigm shift in oncology: targeting the immune system rather than cancer cells.
Shekarian T; Valsesia-Wittmann S; Caux C; Marabelle A
Mutagenesis; 2015 Mar; 30(2):205-11. PubMed ID: 25688113
[TBL] [Abstract][Full Text] [Related]
47. Disillusionments and hopes in the field of biological response modifiers.
Tanneberger S; Pannuti F
Anticancer Res; 1993; 13(1):185-92. PubMed ID: 8476212
[TBL] [Abstract][Full Text] [Related]
48. Recent advances in the management of biotherapy-related side effects: flu-like syndrome.
Haeuber D
Oncol Nurs Forum; 1989; 16(6 Suppl):35-41. PubMed ID: 2687812
[TBL] [Abstract][Full Text] [Related]
49. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1997; 17():287-315. PubMed ID: 9551217
[No Abstract] [Full Text] [Related]
50. Plants, polysaccharides, and the treatment and prevention of neoplasia.
Pelley RP; Strickland FM
Crit Rev Oncog; 2000; 11(3-4):189-225. PubMed ID: 11358267
[TBL] [Abstract][Full Text] [Related]
51. Role of interferon in clinical practice.
Sréter L; Fehér J
Ther Hung; 1991; 39(4):159-66. PubMed ID: 1725832
[TBL] [Abstract][Full Text] [Related]
52. [Immunomodulation in cancer. What do we do and where do we go?].
Rodríguez Orozco AR; Serriteño NM
Rev Alerg Mex; 2005; 52(2):96-101. PubMed ID: 16158783
[TBL] [Abstract][Full Text] [Related]
53. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1993; 14():207-26. PubMed ID: 8312103
[No Abstract] [Full Text] [Related]
54. Biological response modifiers in breast cancer.
Janik JE; Longo DL
Compr Ther; 1991 Dec; 17(12):28-31. PubMed ID: 1790662
[No Abstract] [Full Text] [Related]
55. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1996; 16():239-73. PubMed ID: 8639384
[No Abstract] [Full Text] [Related]
56. [New trends in antineoplastic chemotherapy].
Klener P
Vnitr Lek; 1994 Jun; 40(6):386-90. PubMed ID: 8073651
[TBL] [Abstract][Full Text] [Related]
57. A survey of biotechnology.
Mitchison NA
Ann Ist Super Sanita; 1991; 27(1):3-6. PubMed ID: 1958026
[TBL] [Abstract][Full Text] [Related]
58. Clinical use of biologic response modifiers in cancer treatment: an overview. Part I. The interferons.
Balmer CM
DICP; 1990; 24(7-8):761-8. PubMed ID: 1695795
[TBL] [Abstract][Full Text] [Related]
59. [Disappointments and hopes in tumor therapy with biological response modifiers].
Tanneberger S
Z Arztl Fortbild (Jena); 1992 Jun; 86(11):551-8. PubMed ID: 1621399
[No Abstract] [Full Text] [Related]
60. Biological response modifiers: interferons, interleukins, recombinant products, liposomal products.
Kruth SA
Vet Clin North Am Small Anim Pract; 1998 Mar; 28(2):269-95. PubMed ID: 9556849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
